Halda Therapeutics, based in New Haven, Connecticut, has secured $126 million in Series B extension funding, raising its total to $202 million. This round saw investment from new backers and support from existing investors.
- New and Existing Investors: Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital, and Taiho Ventures joined existing investors Canaan Partners, Access Biotechnology, Elm Street Ventures, and Connecticut Innovations.
- RIPTAC™ Technology: Developed by Professor Craig Crews at Yale, RIPTAC™ employs a “hold and kill” mechanism to precisely target cancer cells, addressing resistance issues in current treatments.
- Pipeline Focus: Halda’s RIPTAC™ platform is geared towards major solid tumors like prostate and breast cancer, with additional programs targeting other cancer types.
- Clinical Trials: The funding will advance two RIPTAC™ candidates into trials for metastatic prostate and breast cancer, targeting cases resistant to current treatments.
Halda Therapeutics is set to make significant strides in cancer treatment with its innovative RIPTAC™ technology, aiming to address critical needs in oncology and improve patient outcomes.
